

## CURRICULUM VITAE

**Name:** Lowell Brian Anthony

**Monday Clinic:**

**Business Address:** Louisiana State University Health Care Network  
2820 Napoleon Ave, Suite 890  
New Orleans, LA 70115

**Clinic Telephone:** (504) 899-6716

**Clinic Fax:** (504) 899-8417

---

**Tuesday Clinic:**

**Business Address:** Louisiana State University Health Care Network  
200 West Esplanade, Suite 200  
Kenner, LA 70062

**Clinic Telephone:** (504) 464-8500

**Clinic Fax:** (504) 464-8525

---

**E-Mail:** [Lantho@lsuhsc.edu](mailto:Lantho@lsuhsc.edu)

**Home Address:** 8 Chateau Pontet Canet  
Kenner, LA 70065-2036

**Home Telephone:** (504) 464-0473

**Home Fax:** (650) 491-0040

**Mobile Telephone:** (504) 606-1820

**Birthdate and Birthplace:** November 21, 1952  
Chattanooga, Tennessee

**Citizenship:** USA

**Education:**

Undergraduate:

1970-1974: B.S. – Chemistry  
King College, Bristol, Tennessee

Graduate:

1975-1979: M.D.  
Vanderbilt University, Nashville, TN

Internship:

1979-1980: Internal Medicine  
Vanderbilt University, Nashville, TN

Residency:

1980-1982: Internal Medicine  
Vanderbilt University, Nashville, TN

Fellowships:

1982-1985: Medical Oncology,  
Vanderbilt University, Nashville, TN

1985-1987: Clinical Pharmacology,  
Vanderbilt University, Nashville, TN

**Certification:**

Internal Medicine, 1983  
Medical Oncology, 1989

**Licensure:**

Licensing Board, Tennessee, MD013153, 1981 - present  
Licensing Board, Louisiana, 11661R, 1996 - present  
State Controlled Substance, Louisiana, #24687, 1996- present  
Drug Enforcement Agency, Federal, #, AA9760984 1981- present

**National Provider Identification Number:**

1184622250

**Awards and Honors:**

Beta Tau Kappa Honor Society  
American Cancer Society Regular Clinical Fellowship Award  
American Cancer Society Spirit Award

**Academic, Professional, and Research Appointments:**

- 1974-1975: Research Technician for Donald S. Coffey, Ph.D.,  
Department of Pharmacology, The Johns Hopkins University,  
Baltimore, MD
- 1976-1977: Cancer Summer Research Program, American Cancer Society
- 1987-1989: Instructor in Medicine, Vanderbilt University, Nashville, TN
- 1987-1991: Full time Staff Physician, Oncology Section, VA Medical Center,  
Nashville, TN
- 1989-1996: Associate Professor of Medicine, Vanderbilt University,  
Nashville, TN
- 1993-1996: Part-time Staff Physician, Oncology Section, Research and  
Development Staff Physician, VA Medical Center, Nashville, TN
- 1996-1998: Acting Director, Division of Hematology/Oncology, Louisiana  
State University, New Orleans, LA
- 1996-2004: Associate Professor of Medicine, Division of Hematology and  
Oncology, Louisiana State University, New Orleans, LA;  
Director of Gastrointestinal and Neuroendocrine Oncology
- 2005-present: Professor of Medicine, Division of Hematology and Oncology,  
Louisiana State University, New Orleans, LA; Director of  
Gastrointestinal and Neuroendocrine Oncology

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 4

**Membership in Professional Organizations:**

Fellow, American College of Physicians  
Member, American Society of Clinical Oncology  
Member, American Federation for Medical Research  
Member, American Association for Cancer Research  
Member, American Society of Hematology  
Member, Stanley S. Scott Cancer Center  
Member, Southwest Oncology Group  
Multinational Association of Supportive Care in Cancer  
Elected Member, Southern Society for Clinical Investigation  
American Society of Clinical Pharmacology and Therapeutics (resigned)

**Teaching Experience/Responsibilities:**

Undergraduate, Graduate, Resident, Fellow, Post-doctoral Instruction

Physical Diagnosis Instructor 7 years

"Special Topics" Pharmacology Course 6 years

Medical Student Faculty Advisor 7 years

Tutor in Diabetes Training Grant 2 years

NCI Short Research Experience 8 years

2-3 Months/yr as In-patient Subspecialty Service

1 Month/yr as General Medicine Service Attending

4 months/yr In-patient Oncology/Hematology Consult Service Attending

12 months/yr In-patient General Clinical Research Center Attending

12 months/yr Out-patient General Oncology MCLNO Clinic (Thursday pm)

Annual Lectures on the Management of Colorectal Cancer, Neuroendocrine Malignancies, Gastric Cancer and Erythropoietin Growth Factors, Clinical Oncology Fellows weekly conference

Network Oncology Communication and Research (NOCR), Atlanta, GA 2001-2004 (4 to 6 lectures / year)

Physicians Education Resource (PER), Dallas, TX 2004-present (1 to 4 lectures / year)

Ethics Rounds Conundrum Series with Dr. Rothschild - Invited Speaker, 2000,  
2003, 2004

Thesis & Dissertation Committees:

Doctoral Thesis Opponent for Eva T. Janson, 5/95  
Uppsala University, Uppsala, Sweden

Post-Doctoral or Post-Residency Fellows Trained:

Michael Bergeron, M.D. 1996 -1997  
Leroy Fredericks, M.D. 1996 -1997  
James Ellis, M.D. 1996 -1998  
Nicole L. Angel, M.D. 1996-1998  
Stephen Beck, M.D. 1998 - transferred to UAB  
Scott Barron, M.D. 1998 - 2001  
Allen Calabresi, M.D. 1998 - 2001  
Mark Charbonnet, M.D. 1999 - 2001  
Sophy Jancich, M.D, 2000 - 2003  
Monique Semien, M.D. 2000 - 2003  
Charles Schloss, M.D. 2001-2004  
Leslie Meng, M.D., 2001-2004  
Navjeet (Shelly) Ghandhok, M.D., 2002-2005  
John Kennedy, M.D., 2002-2005  
Matt McElveen, M.D., 2003-2005  
Sonny Caffey, M.D., 2003-2005  
Kellie Schmeckle, M.D., 2004-2006  
Michael Broussard, M.D., 2004-2006

**University/Professional Leadership and Service:**

School of Medicine Committees

1993-1996	Pharmacy and Therapeutics Committee, Vanderbilt University Hospital
1994-1996	General Clinical Research Center Advisory Committee, Vanderbilt University Hospital
1997-1998	Executive Advisory Board Stanley S. Scott Cancer Center, Louisiana State University Medical Center New Orleans

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 6

- 1997-1998 Search Committee for the Head of the Department of Public Health and Preventive Medicine, Louisiana State University Medical Center, New Orleans
- 1999-2000 Search Committee for the Head of the Department of Pharmacology, Louisiana State University Medical Center New Orleans
- 2000-2002 Cancer Liaison Physician for the Hospital Cancer Program at Medical Center of Louisiana New Orleans, Commission on Cancer, American College of Surgeons
- 1997-present Cancer Committee Medical Center of Louisiana New Orleans Vice-Chairman 1998-1999, Chairman 1999-present
- 1996-present General Clinical Research Center Advisory Committee, Louisiana State University Medical Center New Orleans

Professional Societies Committees

- 1995-1998 Chairman, Hematologic and Neoplastic Diseases Subsection American Society Clinical Pharmacology and Therapeutics
- 1992-1994 Vice-Chairman, Hematologic and Neoplastic Diseases Subsection , American Society Clinical Pharmacology and Therapeutics
- 1992-1995 Publications Committee, American Society Clinical Pharmacology and Therapeutics
- 1995-1997 Membership Committee, ,American Society of Clinical Oncology
- 1995-1997 International Scientific Committee, Medicus Pharmaceuticals, Athens, Greece

Community Service/Activities:

Cancer Liaison Physician for the Hospital Cancer Program at Medical Center of Louisiana New Orleans, Commission on Cancer, American College of Surgeons, 2000-2002

Five live appearances on “Health Matters”, a 30 minute weekly community health education and awareness program, WLAE, New Orleans, LA from 1996-2005; topics discussed: hepatocellular cancer, lung cancer, pancreatic cancer and 2 appearances discussing colorectal cancer

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 7

Clinical Service:

Clinics

VA Oncology Clinic, Nashville, TN, 10 years  
VU Neuroendocrine Tumor Clinic, Nashville, TN, 4 years  
Lions Clinic, LSMC, New Orleans, 1996-1999  
Stanley S. Scott Cancer Center, 2820 Napoleon Ave, GI Oncology Clinic, 2000-  
Aug 2005 with 2 clinics per week  
LSUHSC Multi-disciplinary GI cancer clinic, 3401 North Blvd., Baton Rouge,  
LA Oct 2005 - present  
LSUHSC Multi-specialty Clinic, 3600 Prytania St, Suite 35, Dec 2005 - present  
MCLNO 10<sup>th</sup> Floor Multidisciplinary GI Oncology Clinic, Wed pm, 1996 -1998  
MCLNO 10<sup>th</sup> Floor Hematology Clinic, Fri pm 1996-1997  
MCLNO 10<sup>th</sup> Floor General Oncology Clinic, 1998-2001  
MCLNO 10<sup>th</sup> Floor General Oncology Fellows Clinic, 2001 – Aug 2005

Inpatient Service Activities

VA Medical Service Attending, Nashville, TN, 1987-1996  
VA Oncology Service Attending, Nashville, TN, 1987-1996  
VU Oncology Service Attending, Nashville, TN, 1992-1995  
GCRC Investigator, Nashville, TN, 1987-1996  
GCRC Investigator, New Orleans, LA, 1996-present  
MCLNO, Charity and University Hospitals, New Orleans, LA Attending 1996-  
Aug 2005

Call

8-12 times / year covering Medical Oncology / Hematology Services at MCLNO  
and Memorial Medical Center (Baptist and Mercy Campuses)

**Administrative Responsibilities:**

1996-1998: Acting Director, Division of Hematology/Oncology, Louisiana State  
University, New Orleans, LA

1999- 2005 Chairman of Cancer Committee at MCLNO

**Research Review Committee:**

FDA Orphan Drug Grants Review Panel, 2002, 2003

### **Editorial Activities:**

#### Editorial Board:

The Journal of Peptide Therapy: Index and Reviews

#### Journal Reviewer:

Journal of Nuclear Medicine  
New England Journal of Medicine  
Annals of Internal Medicine  
Clinical Pharmacology and Therapeutics  
Journal of Clinical Oncology Cancer

### **Publications**

#### Refereed

1. **Anthony LB**, Greco FA. Pneumocystis carinii Pneumonia: A complication of Cushing's Syndrome. Ann Int Med, 94:488-89, 1981.
2. **Anthony LB**, Krozely MG, Woodward NJ, Hainsworth JD, Hande KR, Brenner DE, Greco FA, Burish TG. Antiemetic Effect of Oral vs Intravenous Metoclopramide in Patients Receiving Cisplatin: A Randomized Double-blind Trial. J Clin Oncol, 4(1): 98-103, 1986.
3. Hande KR, Combs G, Swingle R, Combs GL, **Anthony LB**. The Effect of Cimetidine and Ranitidine on the Metabolism and Toxicity of Hexamethylmelamine. Cancer Treat Rep, 70:1443-1445, 1986.
4. Brenner DE, **Anthony LB**, Halter S, Harris NL, Collins JC, Hande KR. Effect of allyl alcohol induced sub-lethal hepatic damage upon doxorubicin metabolism and toxicity in the rabbit. Ca Res, 45:3259-3265, 1987.
5. Harris NL, Brenner DE, **Anthony LB**, Collins JC, Halter S, Hande KR. The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. Ca Chemotherapy Pharmacol, 21:323-328, 1988.
6. Hande KR, **Anthony LB**, Hamilton R, Sweetman B, Branch RA. Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit. Ca Res 48:1829-1834, 1988.
7. **Anthony LB**, Koshakji R, Wilkinson G, Wood AJJ. Multiple Pathways of Propranolol's Metabolism are Inhibited by Debrisoquine: Clin Pharm Ther, 46(3): 297-300, 1989.
8. Stratton CW, **Anthony LB**, Johnston PE. Topics in Clinical Pharmacology: A Review of Ceftriaxone: A Long-acting Cephalosporin. Am J Medical Sciences, 296:1-2, 1988.
9. Smith S, **Anthony LB**, Oates J, Pincus T. Musculoskeletal Pain in Carcinoid Syndrome: Resolution after Treatment with the Somatostatin Analogue Octreotide. Ann Int Med, 112(1):66-68, 1990.

10. **Anthony LB**, Long Qi-cai, Struck RF, Hande KR. The effect of cimetidine on cyclophosphamide metabolism in rabbits. Ca Chemotherapy and Pharmacol, 27:125-130, 1990.
11. Zhou HH, **Anthony LB**, Wood AJJ, Wilkinson GR. Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharm, 30(3): 471-475, 1990.
12. Zhou HH, **Anthony LB**, Roden DM, Wood AJJ. Quinidine reduces clearance of (+)-propranolol more than (-)- through marked reduction in 4-hydroxylation. Clin Pharm and Ther, 47(6):686-693, 1990.
13. **Anthony LB**, Johnson DH, Shaff M, Hande KR, Oates JA. Somatostatin analogue Phase I trials in neuroendocrine neoplasms. Acta Oncologica,. 32(2): 217-223, 1993.
14. **Anthony LB**, Boeve TJ, Hande KR. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Ca Chemother and Pharmacol, 36(2): 125-128, 1995.
15. **Anthony LB**, Sharp SC, May ME. Diabetic ketoacidosis in a patient with glucagonoma. Am J Medical Sciences, 309:326-32, 1995.
16. **Anthony LB**, May ME, Oates JA. Lanreotide in the management of hypercalcemia of malignancy. Am J Medical Sciences, 39:312-314, 1995.
17. Harris AG, O'Dorisio TM, Woltering EA, **Anthony LB**, Burton FR, Geller RB, Grendell JH, Levin B, Redfern JS. Consensus Statement: Octreotide dose-titration in secretory diarrhea. Dig Dis Sci 40:1464-1473, 1996.
18. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, **Anthony L**, Khojasteh A, Tapazoglou E, Benedict C, Hahne W. Double blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14:2242-2249, 1996.
19. **Anthony LB**, Martin W, Delbeke D, Sandler M. Somatostatin receptor imaging: predictive and prognostic considerations. Digestion, 57(suppl 1):50-53, 1996.
20. **Anthony LB**. Efficacy and toxicity of high-dose somatostatin analogue therapy. Peptide Therapy, Vol IX, Number 1, 1997.
21. Schonfeld WH, Elkin EP, Woltering EA, Modlin IM, **Anthony LB**, Villa KF, Zagari M. The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and vipoma. Int J of Technology Assessment in Health Care, 14(3):514-25, 1998.
22. Goren MP, **Anthony LB**, Krozely MG, Li JT, Bush DA, Hande KR. Urine and plasma pharmacokinetics of an IV-Oral versus IV mesna administration regimen in lung cancer patients receiving ifosfamide, J Clin Oncol, 16:616-621, 1998.
23. Drougas JG, **Anthony LB**, Blair TK, Lopez RR, Wright JK Jr, Chapman WC, Webb L, Mazer M, Meranze S, Pinson CW. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surgery, 175(5):408-412, 1998.

24. Goren MP, **Anthony LB**, Hande KR, Johnson DH, Brade WP, Li JT, Bush DA, Frazier MW. Pharmacokinetics of an intravenous-oral versus intravenous mesna administration regimen in lung cancer patients receiving ifosfamide. J Clin Oncol, 16:616-621, 1998.
25. McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ, **Anthony LB**. *In situ* radiotherapy with <sup>111</sup>In-pentetreotide: Initial observations and future directions. The Ca J Sci Am 4(2):94-102, 1998.
26. Denney WD, Kemp WE Jr, **Anthony LB**, Oates JA, Byrd BF 3<sup>rd</sup>. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am College of Cardiology. 32(43):1017-22, 1998.
27. Rubin J, Ajani J, Schirmer W, Venook A, Bukowski R, Pommier R, Saltz L, Dandona P, **Anthony L**. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol, 17:600-606, 1999.
28. **Anthony LB**. *In situ* radiotherapy with <sup>111</sup>In-pentetreotide: Results of a Phase II Trial in Gastroenteropancreatic Neoplasms. Tele Lecture Clinics: Peptide Therapy, Peptide Therapy, X(1):10-11, 1998.
29. Espenan GD, Nelson JA, Fisher DR, Diaco DS, McCarthy KE, **Anthony LB**, Maloney TJ, Woltering EA. Experiences with high dose radiopeptide therapy: the health physics perspective. Health Physics, 76(3):225-235, 1999.
30. **Anthony LB**. Long-acting formulations of somatostatin analogues. Italian Journal of Gastroenterology and Hepatology, 31(Suppl. 2):216-218, 1999.
31. Prasad C, Debata C, Imamura M, Schapira DV, **Anthony LB**. Serum Levels of Enterostatins (Val-Pro-Asp-Pro-Arg and Ala-Pro-Gly-Pro-Arg/Val-Pro-Gly-Pro-Arg) are Decreased in Metastatic Carcinoid Neoplasm. Cancer Research Therapy and Control 10: 183-187, 1999.
32. McCarthy, K, Woltering, G, and **Anthony, LB**. In Situ Radiotherapy with <sup>111</sup>In-Pentetreotide: State of the Art and Perspectives. Review Article, Quarterly Journal of Nuclear Medicine, 44(1): 88-95, 2000.
33. Meyers MO, **Anthony LB**, McCarthy KE, Drouant G, Maloney TJ, Espenan GD et al. High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. Southern Medical Journal 2000; 93(8): 809-811.
34. **Anthony LB**. Medical Management of Carcinoid Neoplasms: Present and Future Considerations. Oncology, 2002, 16(9), 13-14.
35. **Anthony LB**, Woltering EA, Espenan GD, Cronin M, Maloney TJ, McCarthy KE. Indium-111 pentetreotide prolongs survival in gastroenteropancreatic malignancies. Seminars in Nuclear Medicine 2002; 32(2): 123-132.
36. Gulec SA, Mountcastle TS, Frey D, Cundiff JD, Mathews E, **Anthony L**, O'Leary JP, Boudreaux JP. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. American Surgeon. 2002; 68(8): 667-71. discussion 671-2, 2002
37. Sodes S, Kennedy JM, Kishner S, Lopez FA, **Anthony L**. Severe Progressive Weakness in a 58-Year-Old Man. J La State Med Soc. 2002; 154(6): 292-5.

38. **Anthony LB.** New strategies for the prevention and reduction of cancer treatment-induced diarrhea. *Seminars in Oncology Nursing* 2003; 19(4), Suppl 3: 17-21.
39. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, **Anthony LB**, Pauwels S, Kvols LK, O'Dorisio TM, Valkema R, Bode L, Chinol M, Maecke HR, Krenning EP. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogues. *J Nucl Med* 2005; 46: 62S-66S.
40. Boudreaux JP, Putty B, Frey DJ, Woltering E, **Anthony L**, Daly I, Ramcharan T, Lopera J, Castaneda W. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. *Annals of Surgery* 2005; 241(6):839-45; discussion 845-6.
41. Rosenoff SH, Gabrail NY, Conklin R, Hohneker JA, Berg WJ, Warsi G, Maloney J, Benedetto JJ, Miles EA, Zhu W, **Anthony L.** A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. *The Journal of Supportive Oncology* 2006 4(6):289-94.
42. **Lowell Anthony**, Joanne Bowen, Adam Garden. New Thoughts on the Pathobiology of Regimen-Related Mucosal Injury, *Journal of Supportive Care* 2006; 14: 516-518.
43. **Anthony L.** Irinotecan Toxicity. *Current Opinion in Supportive and Palliative care.* April 2007 1(1):35-39.

Publications in Press:

Publications Submitted:

1. **LB Anthony**, N Gabrail, H Ghazal, DV Woytowitz, MS Flam, A Drelichman, DM Loesch, L Boros, DA Niforos, A Mangione for the Iron Sucrose Study Group. IV Iron Sucrose or No Iron Treatment for Anemia Due to Cancer and/or Chemotherapy in Erythropoiesis Stimulating Agent Treated Patients. Submitted *JCO*, Mar 7, 2007.

Publications in Progress:

1. Thomas MB, Langleben A, Rinaldi D, **Anthony L**, Irwin D, Lassere Y, Hoff P. Phase II Study of UFT + Leucovorin Given as a Twice-Daily Regimen in the Treatment of Patients with Metastatic Colorectal Cancer.
2. Schloss C, Cronin M, **Anthony LB.** Phase Ib Clinical Trial with Thymitaq administered in a dose intensification schedule in patients with advanced cancer.

Nonreferred

1. **Anthony LB.** Medical simulations in the diagnosis and management of gastrointestinal malignancies. InterMed Press, Division of InterMed Inc, Darien, Connecticut. Oct. 2001.
2. Maroun JA, **Anthony LB**, Blais N, Burkes R, Dowden S, Shah A, Thirlwell MP. “Optimizing the Management of Chemotherapy-Induced Diarrhea: Prophylaxis for patients with colorectal cancer on adjuvant chemotherapy”. First Report of the Working Group on Chemotherapy-Induced Diarrhea. International Working Group Meeting during American Society of Clinical Oncology Annual Meeting, Chicago May 2003.
3. Maroun JA, **Anthony LB**, Blais N, Burkes R, Dowden S, Shah A, Thirlwell MP “Prevention and Management of Diarrhea in Colorectal Cancer Patients” Second Report of the Working Group on Chemotherapy-Induced Diarrhea. International Working Group Meeting during American Society of Clinical Oncology Annual Meeting, Chicago May 2003.
4. **Anthony LB.** “The Expanding Role of Octreotide in Oncology” Nov. 2003.
5. **Anthony LB.** “A Patient Living with Carcinoid Syndrome” The Value of Early Symptom Recognition and the Benefits of Treatment” Feb 2004.
6. **Anthony LB.** “Carcinoid Tumors and Carcinoid Syndrome: A Comprehensive Guide to Diagnosis and Management” Mar 2004.
7. **Anthony L.** “Fluoropyrimidines in the treatment of colorectal cancer.” Educational Symposium presented on April 28<sup>th</sup>, 2005, Satellite Symposium as part of the Annual Meeting for Oncology Nursing Society, Orlando, FL.

Books & Chapters:

1. Goren MP, Goodman TL, **Anthony LB.** Clinical pharmacology of oral mesna. The Role of Clinical Pharmacology in Pediatric Oncology, ed. by R. Riccardi and J. Borsi, 111-118, 1991.
2. **Anthony LB.** Nausea and Vomiting. Conn's Current Therapy. Ed. Robert E. Rakel. W.B. Saunders Co., pp. 5-10, 1993.
3. **Anthony LB.** Nausea and Vomiting. Conn's Current Therapy. Ed. Robert E. Rakel. W.B. Saunders Co., pp. 5-10, 1994.
4. Roberts LJ II, **Anthony LB**, Oates, JA. Disorders of vasodilator hormones: the carcinoid syndrome and mastocytosis. Williams Endocrinology, 9<sup>th</sup> Ed., Chapter 37: 1711-1732, 1998.
5. **Anthony LB.** Medical uses of octreotide acetate long acting formulation. Advances in Oncology, Eds SWJ Lamberts & L. Dogliotti, 2002:73-79.
6. **Anthony LB.** Nausea and Vomiting. Conn's Current Therapy. Ed. Robert E. Rakel. W.B. Saunders Co., 2003.
7. **Anthony LB.** Medical Uses of Octreotide Acetate Long Acting Formulation, edited by Expanding the Role of Octreotide in Clinical Oncology Symposium, Noordwijk, The Netherlands, 2003.
8. **Anthony LB.** Forward, Essentials of Clinical Oncology. Amil Shah, MDCM, FRCPC, FACP, British Columbia Cancer Agency, 2004.

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 13

9. **Anthony L**, Lozan R, Lin EH. Medical Management of Chemotherapy-Induced Diarrhea. Color-Matrix Cancer Staging and Treatment Handbook, 3<sup>rd</sup> edition. Edward H. Lin, MD, Richard Lozano, RPh, Daniel D. Karp, MD, 2004. 143.

Videos & Multimedia:

"Cancer Chemotherapy: Advances in the Management of Nausea and Vomiting"; 1985, A.H. Robins, Co., Richmond, VA

"Sandostatin: Combining Pharmacologic Action with Clinical Benefit"; 1992, Sandoz Pharm. Corp., East Hanover, NJ

"Management of GEP Endocrine Tumors"; 1993, Vanderbilt University Grand Rounds, Nashville, TN

"Incorporating Somatostatin Receptor Scintigraphy into Neuroendocrine Cancer Management", June 1995.

"Neuroendocrine Tumor Case Review: Metastatic Neuroendocrine Pancreatic Tumor", June 1995.

"Current Approaches in the Management of Neuroendocrine Neoplasms"; 1994, M. D. Anderson Cancer Center, The University of Texas Medical Center, Houston, TX

"Therapeutic <sup>111</sup>Indium-pentetreotide for Somatostatin Receptor Expressing Neoplasms: Patient Experiences", LSU Medical Center, New Orleans, LA

"Carcinoid Syndrome" CME video sponsored by Novartis, in progress 9/99

"The Management of Adjuvant Colorectal Cancer with Chemotherapy Induced Diarrhea" CD ROM, Network for Oncology Communication and Research, 2001.

"Impact of Diarrhea on Quality of Life" Nov 2002.

"The Early Diagnosis of Carcinoid Tumors" Guest appearance on The Johnny Carcinoid Show, Las Vegas, NV, Jan 2003.

"Carcinoid Syndrome Management in the Octreotide Acetate LAR Era" in conjunction with Texas Carcinoid Support Member, Carol-Anne Wilson, March 2005.

“Early Diagnosis and Management of Carcinoid Tumors”, American Gastroenterological Association Café, , P. Jay Pasricha, MD (Program Director/Moderator), Lowell Anthony, MD; David Metz, MD; Irvin Modlin, MD, PhD, May 2005.

Papers Presented & Abstracts:

1. **Anthony LB**, Krozely MG, Woodward NJ, Hainsworth JD, Hande KR, Brenner DE, Greco FA, Burish TG. Antiemetic Effect of Oral (PO) vs. Intravenous (IV) Metoclopramide in Patients Receiving Cisplatin: A Randomized Double-blind Trial: Proc Am Soc Clin Oncol, Vol. 3 abstract #404, 1984. Oral presentation at the 20<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, Toronto, Canada, May 1984.
2. **Anthony LB**, Krozely MG, Burish TB, Combs GL, Brenner DE, Stein RS, Wood AJJ, Hande KR. Metoclopramide by Continuous Infusion: Method to Correlate Serum Levels with Antiemetic Protection: Proc Am Soc Clin Oncol, Vol. 5 abstract # 991, 1986.
3. Brenner DE, **Anthony LB**, Halter S, Harris L, Collins JC, Hande KR. The Effect of Allyl Alcohol (allyl) Induced Hepatic Injury upon Doxorubicin (Dox) Pharmacology in Rabbits (RAB): American Society for Clinical Pharmacology and Therapeutics, abstract A17, 1986.
4. Carey MP, Krozely MG, **Anthony LB**, Greco FA, Burish TG. Prevention of Conditioned Nausea and Vomiting by Behavioral Treatment: Proc Am Soc Clin Oncol, Vol. 5, abstract # 990, 1986.
5. Hande KR, Sweetman B, Brenner DE, **Anthony LB**, Combs L, Branch R. Evidence for Glucuronidation of Etoposide: Proc Am Soc Clin Oncol, Vol. 5, abstr 157, 1986.
6. Harris NL, Brenner DE, **Anthony LB**, Collins JC, Hande KR. The Influence of Ranitidine on the Pharmacokinetics and Toxicity of Doxorubicin in Rabbits: Proc Am Soc Clin Oncol, Vol. 5, abstract # 158, 1986.
7. Brenner DE, Harris NL., **Anthony LB**, Halter S, Collins JC, Hande KR. Effect of Hepatic Dysfunction upon Doxorubicin Pharmacology in Rabbits: Proc Am Assoc Can Res, Vol. 27, abstract #964, 1986. Poster presentation at the 22<sup>nd</sup> Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 1996.
8. **Anthony LB**, Koshakji R, Wilkinson G, Wood AJJ. Multiple Pathways of Propranolol's Metabolism are Inhibited by Debrisoquine: Clin Res, Vol. 35, 372A, 1987.
9. **Anthony LB**, Krozely M, Hande K, Greco FA, Burish T. Metoclopramide vs Prochlorperazine in Patients Receiving Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind Trial: Proc Am Soc Clin Oncol, Vol. 6, 1065, 1987.

10. Brenner DE, **Anthony LB**, Hande KR. Prediction of Acute Doxorubicin Toxicity from Human Plasma Pharmacokinetics: Proc Am Assoc Can Res Vol. 28, 138, 1987. Poster Presentation at the Annual Meeting of the American Association of Cancer Research.
11. **Anthony LB**, Wood AJJ, Hande KR. Longitudinal Effects of Cyclophosphamide on Aminopyrine and Antipyrine Metabolism: Clin Res, Vol. 35, 373A, 1987.
12. **Anthony LB**, Long QC, Struck RF, Hande KR. Cimetidine Increases Cyclophosphamide Metabolite Exposure. Proc Am Assoc Can Res Vol. 29, #1044, 1988. Poster presentation at the Annual Meeting of the American Association of Cancer Research.
13. **Anthony LB**, Nace GS, Stone WJ, Ritter SK, Wood AJJ. Indecainide Clearance is Reduced in Renal Impairment. Clin Pharm Ther, Vol. 43, 129, 1988. Poster Presentation at the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics.
14. **Anthony LB**, Long QC, Hande KR. Cimetidine Does Not Inhibit Cyclophosphamide's in vitro Metabolism. Clin Pharm Ther, abstract PIIA-3, 1989. Poster Presentation at the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics.
15. **Anthony LB**, Long QC, Collins JC, Guengerich FP, Hande KR. Cyclophosphamide's metabolism may cosegregate with dapsone hydroxylation. Proc Am Assoc Can Res, Vol. 30, #2123, 1989. Poster presentation at the Annual Meeting of the American Association of Cancer Research, June 1989, San Francisco, CA.
16. **Anthony LB**, Cox SS, Roberts LJ, Hande KR, Oates JA. Octreotide inhibits 5-HIAA secretion and improves quality of life in carcinoid syndrome. Proc Am Soc Clin Oncol, Vol. 8, 1134, 1989. Poster Presentation at the 25<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, May 1989, San Francisco, CA
17. **Anthony LB**, Long QC, Nickel L, Hande KR. Limited sampling model predicts cyclophosphamide area under the curve but not cyclophosphamide metabolite exposure. Proc Am Soc Clin Oncol, Vol. 9, #269, 1990. Oral Presentation at the 26<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, May 1990, Washington, D.C.
18. **Anthony LB**, Nickel LA, Hande KR. Calcium channel antagonists and cyclophosphamide metabolism: in vitro studies with rabbit hepatic microsomes. Proc Am Assoc Can Res, Vol. 31, #2262, 1990. Poster Presentation at the Annual Meeting of the American Association of Cancer Research, May 1990, Washington, D.C.
19. **Anthony LB**, Winn SD, Krozely MG, Johnson DH, Oates JA. Relationship of octreotide dose to its toxicity and efficacy in carcinoid syndrome. Proc Am Soc Clin Oncol, Vol. 10, #387, 1991.
20. **Anthony LB**, Smith MM, Winn SD, Hande KR, Oates JA. Octreotide's dose ranging effect on blood glucose and pharmacokinetics. Clin Pharm Ther, presented 3/92.

- Poster Presentation at the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics.
21. **Anthony LB**, Winn SD, Johnson DH, Hande KR, Oates JA. Octreotide's antitumor efficacy and Phase I trial in carcinoid syndrome. International Conference on Biology and treatment of gastrointestinal malignancies. Frankfurt, Germany, Feb. 4-7, 1992. Oral and poster presentations.
  22. **Anthony LB**, Winn SD, Johnson DH, Jones RA, Hande KR, Oates JA. Continuous subcutaneous octreotide infusion for carcinoid tumor/syndrome. Proc Am Soc Clin Oncol, Vol 11:168, abstract # 485. Poster Presentation at the 28<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology May 1992, San Diego, CA.
  23. Hande K, Long Q, **Anthony L**. Cyclophosphamide (CPA) metabolism in patients deficient in the P450-IID6 microsomal isoenzyme Proc Am Soc Clin Oncol, the American Society of Clinical Oncology, 5/1992, Vol 11:116, abstract # 286.
  24. **Anthony LB**, Krozely MG, Johnson DH, Shaff MI, Hande KR, Oates JA. Phase I trial of somatuline in neuroendocrine neoplasms. Proc Am Soc Clin Oncol, accepted for poster presentation, the American Society of Clinical Oncology 29<sup>th</sup> annual meeting, 5/1993, Vol 12:202, abstract # 598.
  25. **Anthony LB**, Garrow GC, Davenport MC, Struck RF, Hande KR. Metabolic routes of ifosfamide metabolism in an isolated perfused rat liver model. Proc Am Assoc Can Res, Vol 33, abstract #2411, 1992.
  26. **Anthony LB**, Winn SD, Mazer MJ, Meranze SG, Johnson DH, Jones RA, Hande KR, Oates JA. Insulin-like growth factor (IGF-1) is released after hepatic artery chemoembolization of neuroendocrine neoplasms. Proc Am Soc Clin Oncol, the American Society of Clinical Oncology, 5/1993, Vol 12:117, abstract # 269.
  27. Drougas JG, **Anthony LB**, Wright JK, Chapman WC, Pinson C.W. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Poster Presentation at The Society of Surgical Oncology, 1994 Annual meeting, Houston, TX, 3/94.
  28. Chong WK, Cole TC, Denny WD, Mazer MJ, Shaff MI, Arildsen RC, **Anthony, L.B.** Radiology of the carcinoid syndrome. 79th Annual Meeting of the Radiological Society of North America, 11/93. (Scientific Exhibit given certificate of Merit)
  29. **Anthony LB**, Mazer MJ, Meranze SG, Johnson DH, Hande KR, Oates JA, Pinson CW. Hormonal markers following hepatic artery chemoembolization of neuroendocrine neoplasms. Proc Am Assoc Can Res Vol. 35:270, #1612, 1994. Poster Presentation the Annual Meeting of the American Association of Cancer Research, May 1994.
  30. **Anthony LB**, Winn SD, Mazer MJ, Pinson CW, Johnson DH, Hande KR, Oates JA. High-dose octreotide plus cytotoxic chemotherapy in the management of metastatic neuroendocrine neoplasm. Proc Am Soc Clin Oncol Vol 13:190, #550, 1994.
  31. Paul DM, Johnson DH, Hande KR, Stewart S, **Anthony L**, Arteaga C, Murphy, B, DeVore R. Carboplatin and taxol: A well-tolerated regimen for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol Vol 13:352, #1181, 1994.

32. **Anthony LB**, Winn SD, Johnson DH, Kande KR, Oates JA. Chronic "high-dose" octreotide in neuroendocrine neoplasms. Presented at the 8th NCI-EORTC symposium on new drugs in cancer therapy, Free University, Amsterdam, 3/15-18/1994, Proc 8th NCI-EORTC Symposium (abstract # 267).
33. **Anthony LB**, Martin W, Winn S, Delbeke D, Sandler M, Oates JA. Somatostatin receptor scintigraphy predicts hormonal response in neuroendocrine cancer. accepted for poster presentation, American Association for Cancer Research, Proc Am Assoc Can Res, 1995 annual meeting, Toronto, Canada.
34. **Anthony LB**, Martin W, Arildsen R., Shaff M, Clanton J, Delbeke D, Sandler M. Somatostatin receptor scintigraphy in neuroendocrine neoplasms. Clin Pharm Ther, American Society for Clinical Pharmacology and Therapeutics, accepted for poster presentation 1995 annual meeting, San Diego, CA.
35. Belas FJ, Goldthwaite CA, **Anthony LB**, Blair IA. Identification and quantification of cyclophosphamide using LC/ESI/MS/MS). Proceedings 43rd ASMS Conference Mass Spectrometry, Allied Topics, Atlanta, GA 1995.
36. Goldthwaite CA, Belas FJ, Phillips MA, **Anthony LB** and Blair IA. A sensitive LC/ESI/MS/MS assay for the antineoplastic agent ifosfamide. Proceedings 43rd ASMS Conference Mass Spectrometry, Allied Topics, Atlanta, GA, 1995.
37. Martin WH, Delbeke D, **Anthony LB**, Sandler MP. Somatostatin receptor scintigraphy in the evaluation of carcinoid syndrome. Proceeding 42nd Annual Society of Nuclear Medicine, Minneapolis, MN, 1995.
38. **Anthony LB**, Shyr Y., Winn SD, Hande KR, Johnson DH, Jones RA, Oates JA. Malignant carcinoid syndrome: Survival in the somatostatin analogue era. Annual meeting Los Angeles, CA, 5/95, Proc Am Soc Clin Oncol Vol 14, page 193, 1995.
39. Goldthwaite CA, Belas FJ, Hsieh FY, Phillips MA, **Anthony LB** and Blair IA. Quantitation of the antineoplastic agents cyclophosphamide and ifosfamide using liquid chromatography/chemical reaction interface mass spectrometry (LC/CRI MS) and liquid chromatography/tandem mass spectrometry (LC/MS/MS). 1995 Gordon Conference on Chemotherapy of Experimental and Clinical Cancer, July 1995.
40. Martin WH, Delbeke D, **Anthony LB**, Sandler MP. Somatostatin receptor scintigraphy in the evaluation of carcinoid syndrome. 81st Scientific Assembly and Annual Meeting of the Radiological Society of North America , oral presentation, November, 1995.
41. **Anthony LB**, Bennett RE, Hande KR. Cytochrome P-450 in vitro activation of cyclophosphamide (CPA) and ifosfamide (IFOS). Clin Pharm Ther, 60: 145, 1996. Poster Presentation at the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Orlando, FL, Mar 1996.
42. **Anthony LB**, Chapman WC, Shyr Y, Mazer MJ, Meranze SG, Jones RA, Pinson CW. Survival following hepatic artery chemoembolization in the management of progressive metastatic neuroendocrine neoplasms. Proc Am Soc Clin Oncol Vol 15: 231 1996.

43. Goren MP, **Anthony LB**, Goodman TL, Chang Y-C, Bush DA, Brade WP. Multicenter pharmacokinetic study of mesna tablets in patients treated with ifosfamide. Submitted as late breaking abstract, Proc Am Soc Clin Oncol Vol 15, 1996.
44. **Anthony LB**, Shyr Y, Winn SD, Oates JA. Octreotide acetate (OA) in the management of malignant carcinoid syndrome (CS), Accepted for poster presentation at the Annual Meeting of the European Society of Medical Oncology, October 1996, Vienna, Austria.
45. **Anthony LB**, Petryk L, Olejarczyk J, Foulds, EC, Schran, HF. Pharmacokinetics of octreotide acetate long acting release (OALAR) in volunteers. Clin Pharm Ther, 61: 144, 1997. Poster Presentation the Annual Meeting of The American Society of Clinical Pharmacology and Therapeutics, March 1997.
46. Rubin J, Ajani J, Schirmer W, Venook A, Bukowski R, Pommier R, Saltz L, Dandona P, **Anthony L**. Results of "A randomized study of the safety, tolerability and efficacy of multiple double-blind dose levels of octreotide acetate LAR given at four-week interval vs open-label subcutaneous octreotide in malignant carcinoid syndrome." Proc Am Soc Clin Oncol Vol 16, 1997. Oral Presentation at the 34<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May 1997.
47. **Anthony L**, Ajani J, Schirmer W, Venook A, Bukowski R, Pommier R, Saltz L, Dandona P, Rubin J. Octreotide acetate long acting release (OALAR): 5-HIAA response in a randomized multi-center double-blind trial in carcinoid syndrome. Accepted for poster presentation, 1997 Annual Meeting of the Endocrine Society, Minneapolis, MN.
48. Lobrano L, Higgins J, **Anthony L**, Woltering E, Neitzschman H, McCarthy K. CT manifestations of metastatic carcinoid syndrome with radiopharmaceutical receptor and pathological correlation. Poster Presentation at the 98<sup>th</sup> Annual Meeting American Roentgen Ray Society, Chicago, IL, Supplement to the American Journal of Roentgenology, Vol 170, No. 4, p. 75, 1998.
49. Goren MP, **Anthony LB**, Goodman TL, Johnson DH, Chang AY, Bush DA, Frazier MW, Junge K, Venhaus RR, Brade WP. Uroprotection and urinary pharmacokinetics of an IV-Oral mesna regimen in patients receiving ifosfamide. ." Proc Am Soc Clin Oncol Vol 17, p 219a, 1998. Oral Presentation at the 34<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, May 1998, San Diego, CA.
50. McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ, **Anthony LB**. In situ radiotherapy with 111In-pentetreotide in gastroenteropancreatic (GEP) Neoplasms: Report of a pilot trial. Proc Am Soc Clin Oncol Vol 17, p 296a, 1998.
51. **Anthony L**, Ajani J, Schirmer W, Venook A, Bukowski R, Pommier R, Saltz L, Dandona P, Rubin J. Phase IV open-label, long-term trial of the safety, tolerability, and efficacy of octreotide acetate LAR injected at 4-week intervals in malignant carcinoid syndrome. Proc Am Soc Clin Oncol Vol 17, p 268a, 1998. Poster Presentation at the 34<sup>th</sup> Annual Meeting fo the American Society of Clinical Oncology, May 1998, San Diego, CA.

52. Rubin J, Ajani J, Schirmer W, Venook A, Bukowski R, Pommier R, Saltz L, Dandona P, **Anthony L**. A randomized study of the safety, tolerability and efficacy of multiple double-blind dose levels of octreotide acetate LAR given at four-week intervals vs open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. *Cancer Investigation*, Vol 16, suppl 1, p 78, 1998.
53. **Anthony LB**, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Efficacy of high dose <sup>111</sup>In-pentetreotide therapy for somatostatin receptor expressing neoplasms: Report of the first North American clinical trial. Accepted for presentation, 12<sup>th</sup> International Symposium on Regulatory Peptides, Mackinac Island, MI, September 1998.
54. Meyers MO, **Anthony LB**, McCarthy KE, Espenan GD, Drouant G, Anthony CT, Woltering EA. The first North American patient treated with high dose <sup>111</sup>Indium-pentetreotide therapy for atypical neuroendocrine tumors. Accepted for presentation, 12<sup>th</sup> International Symposium on Regulatory Peptides, Mackinac Island, MI, 1998.
55. McCarthy KE, Espenan GD, Cronin M, **Anthony LB**, Woltering EA. Visualization of somatostatin receptor-positive lesions with <sup>111</sup>Indium-pentetreotide is dose-dependent. Accepted for presentation, 12<sup>th</sup> International Symposium on Regulatory Peptides, Mackinac Island, MI, 1998.
56. Woltering EA, **Anthony LB**, Espenan GD, Cronin M, McCarthy KE. Renal toxicity of high-dose <sup>111</sup>Indium-pentetreotide therapy: Report of the first North American clinical trial. Accepted for presentation, 12<sup>th</sup> International Symposium on Regulatory Peptides, Mackinac Island, MI, 1998.
57. **Anthony LB**, Woltering E.A, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Myelosuppressive effects of <sup>111</sup>Indium-pentetreotide therapy for somatostatin receptor expressing neoplasms. 40<sup>th</sup> Annual Meeting of the American Society of Hematology, Miami, FL. Dec 1998.
58. **Anthony LB**, Woltering E.A, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. SomatoTher<sup>TM</sup> (<sup>111</sup>In-pentetreotide) therapy produces biochemical responses and prolongs survival in patients with gastroenteropancreatic malignancies. Accepted for poster presentation, 35<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA. *Proc Am Soc Clin Oncol* Vol 18, p 242a, 1999.
59. Johnson PJ, Leung TWT, Vogl TJ, Gores G, Thuluvath PJ, Giovannini M, O'Grady J, **Anthony L**, Benson A, Forlenza T, Mayer D. Percutaneous administration of cisplatin/epinephrine injectable gel for treatment of intrahepatic lesions of hepatocellular carcinoma. *Proc Am Soc Clin Oncol* Vol 19, 2000.
60. Thomas MB, Langleben A, Rinaldi D, **Anthony L**, Irwin D, Lassere Y, Hoff P. a Phase II Study of UFT + Leucovorin Given as a Twice-Daily (BID) Regimen in the Treatment of Patients (Pts) with Metastatic Colorectal Cancer (MCC). *Proc Am Soc Clin Oncol* Vol 20, abstract 564, 2001. Poster Presentation the 37<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, May 2001, San Francisco, CA.
61. **Anthony LB**, Vance D, Rubin J, Ajani JA, Stridsberg M. 5-HIAA versus chromogranin A as biochemical markers in the malignant carcinoid syndrome: results

- from a randomized multi-institutional clinical trial. Proc Am Soc Clin Oncol Vol 21, abstract 1664, 2002. Accepted for poster presentation at the 38<sup>th</sup> Annual Meeting of American Society of Clinical Oncology, May 2002, Orlando, FL.
62. Boudreaux P, Frey, Matthews E, **Anthony LB**. Octreotide acetate LAR and debulking for progressive well-differentiated neuroendocrine malignancies. Proc Am Soc Clin Oncol Vol 21, abstract 2199, 2002.
  63. **Anthony L**, Carlisle T, Pommier R, Benson A, Rafferty T, Rothermel J. An open-label phase Ia trial evaluating the safety and efficacy of EPO906 as therapy in patients with metastatic carcinoid and other neuroendocrine tumors. Proc Am Soc Clin Oncol Vol22, 2003.
  64. Theodossiou C, Fayard N, **Anthony L**, Sartin B. CD-117 expression in carcinoid tumors. Proc Am Soc Clin Oncol Vol22: abstr 1520, p 378, 2003.
  65. Le L, Linares L, Andrews S, **Anthony L**. Indium-111 pentetreotide therapy in somatostatin receptor expressing neoplasms: Results from clinical practice. Proc Am Soc Clin Oncol Vol23, abstract 4269, 2004.
  66. Rosenoff S, Gabrail N, Conklin R, Hohneker J, Berg W, Hedrick J, Warsi G, Benedetto J, Zhu W, **Anthony L**. A multicenter, randomized trial of long-acting octreotide (LAR) in the treatment of chemotherapy-induced diarrhea (CTID). Proc Am Soc Clin Oncol Vol23, abstract 8109, 2004. Poster Presentation at the 40<sup>th</sup> Annual Meeting of the American Society of Clinical Oncology, June 2004, New Orleans, LA.
  67. **Anthony LB**, Stafford S, Cronin M, Grossman A, Woltering E. Octreotide LAR doses used in clinical practice: Results from an internet survey and a clinical practice. Proc Am Soc Clin Oncol Vol23, abstract 4274, 2004.
  68. Le L, Linares L, Andrews S, McCarthy KE, **Anthony LB**. In-111 pentetreotide therapy in refractory sst2+ well-differentiated neuroendocrine neoplasms in a community hospital. Abstract # 444. Oral Presentation at the Annual Meeting of the Society of Nuclear Medicine, Philadelphia, PA, June 2004.
  69. **Anthony LB**, Kang T, Gandhok N. Malignant carcinoid syndrome: survival in the somatostatin analog era. Poster Presentation at the ASCO GI 2<sup>nd</sup> Annual Meeting, Hollywood, FL, January, 2005.
  70. **Anthony LB**, Kang T, Shyr Y. Malignant carcinoid syndrome: survival in the octreotide LAR era. Abstract # 4084. Poster Presentation at the 41<sup>st</sup> Annual Meeting of the American Society of Clinical Oncology, May 2005, Orlando, FL.
  71. Kvols L, Oberg K, de Herder W, **Anthony L**, Glusman J, Tran L, Wiedenmann B. Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. Abstract # 8024, Poster Presentation at the 41<sup>st</sup> Annual Meeting of the American Society of Clinical Oncology, May 2005, Orlando, FL.
  72. Kvols L, Wiedenmann B, Oberg K, Glusman JE, O'Dorisio TM, Reha A, de Herder W, Gao B, Arnold R, **Anthony L**. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or

- resistant to octreotide LAR: Preliminary Results of a Phase II study. Poster presentation, Jan 2006, GI ASCO, San Francisco, CA and submitted to the 42<sup>nd</sup> Annual Meeting of the American Society of Clinical Oncology, June 2006, Atlanta, GA.
- 73. Anthony LB**, Cronin M, O'Dorisio T, O'Dorisio S. An open-label phase II study evaluating the safety and efficacy of PTK787 in patients with progressive metastatic neuroendocrine cancer. Submitted 42<sup>nd</sup> Annual Meeting of the American Society of Clinical Oncology, June 2006, Atlanta, GA.
- 74. Anthony LB**, Gabrail N, Ghazal H, Woytowicz DV, Flam MS, Drelichman A, Loesch DM, Boros L, Niforos DA, Mangione A for the Iron Sucrose Study Group. IV iron sucrose or no iron treatment for anemia due to cancer and/or chemotherapy in erythropoiesis stimulating agent treated patients. Poster presentation at the 43<sup>rd</sup> Annual Meeting of the American Society of Clinical Oncology, June 2007, Chicago, IL.

**Seminars & Invited Presentations:**

- Feb 1992: Frankfurt, Germany, International Conference on Biology and treatment of gastrointestinal malignancies: "Octreotide's antitumor efficacy and Phase I trial in carcinoid syndrome"
- Jun 1992: Lofoten, Norway, Third International Workshop on Neuroendocrine Tumors - Recent Advances in Diagnosis and Treatment: "Phase I Somatostatin Analogue Clinical Trials in Neuroendocrine Neoplasms"
- Sept 1992: Milan, Italy, National Cancer Institute: "The Management of Gastroenteropancreatic and other Neuroendocrine Tumors"
- Sept 1992: Paris, France, Ipsen Pharmaceuticals, "Lanreotide Phase I Trial in Neuroendocrine Malignancies"
- Oct 1992: Duke University, Medical Oncology Grand Rounds: "Somatostatin Analogues in the Management of Neuroendocrine Tumors"
- Oct 1992: UCSF, Mt. Zion, Surgical Grand Rounds, San Francisco, CA: "Targeting Growth Factors in Controlling Neoplastic Cell Growth"
- Nov 1992: University of Florida, Gainesville, Medical Oncology Patient Management Seminar: "Targeting the Somatostatin Receptor to Control Neoplastic Cell Growth"

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 22

- Nov 1992: University North Carolina, Chapel Hill, Medical Oncology Research Seminar: "Phase I Somatostatin Clinical Trials in Hormonally Active Neoplasms"
- Dec 1992: Ohio State University, Columbus, OH, Endocrine Research Conference: "Peptides as Antineoplastic Therapy: Completing the Loop"
- Feb 1993: Howard University, Washington D.C., Medical Oncology Seminar: "The Management of Carcinoid Syndrome"
- Feb 1993 University of Miami, Medical Oncology Grand Rounds: "Targeting Growth Factors in Cancer Therapy"
- Apr 1993 Medical College of Georgia, Augusta, GA, Medical Grand Rounds, "Novel Approaches to the Management of Hypercalcemia of Malignancy"
- May 1993 Cleveland Clinic, Cleveland, OH, Medical Oncology Seminar: "Management of GEP Endocrine Tumors: Somatostatin Congener Clinical Trials"
- May 1993 Mt. Sinai School of Medicine, New York, NY, Medical Oncology Grand Rounds, "Targeting the Somatostatin Receptor in the Treatment of Neoplastic Diseases"
- Jun 1993 University of South Alabama, Mobile, AL, Medical Grand Rounds, "The Management of GEP Endocrine Tumors: Carcinoid Syndrome and Islet Cell Malignancies"
- Jul 1993 University of Florida, Jacksonville, FL, Medical Grand Rounds, "The Medical Management of Hormonally Active Neoplasms"
- Jul 1993 Teleconference originating from Nashville with regional sites including Lenox Hill Hospital, NYC, Univ. of Arkansas, Little Rock, Univ. of West Virginia, Medical College of Virginia, Richmond, Univ. of North Carolina, Chapel Hill, Univ. Alabama, Birmingham, "The Management of Carcinoid Neoplasm"
- Sept 1993 Vanderbilt University Medical Grand Rounds, "Management of GEP Endocrine Tumors"
- Oct 1993 Vanderbilt Endocrinology Grand Rounds, "Phase I/II Somatostatin Analogue Clinical Trials in Neuroendocrine Cancer"

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 23

- Jan 1994 M. D. Anderson Cancer Center, The University of Texas Medical Center, Houston, TX, "Current Approaches in the Management of Neuroendocrine Neoplasms"
- Mar 1994: Frankfurt, Germany, "The Somatostatin Peptides: Novel Agents in the Treatment of Neoplastic Diseases," Asta Medica, AG
- Mar 1994: ASCPT Symposium chairman, New Orleans, LA "Targeting Growth Factors as Therapy for Neoplastic Diseases"
- Oct 1994: Vanderbilt University Pharmacology/Cancer Center Research Seminar, "The Management of Neuroendocrine Neoplasms: from Bedside to Bench"
- Nov 1994 Wayne State University, Detroit Medical Center, Harper Hospital, Oncology Division Seminar, "Somatostatin Receptor Scintigraphy in the Management of Hormonally Active Neoplasms"
- Jan 1995 Vanderbilt University Clinical Pharmacology Seminar, "Antineoplastic Agents Undergoing Oxidative Metabolism: Clinical Implications"
- Feb 1995 Vanderbilt University Medical Research Seminar, "Neuroendocrine Cancer: A Model for Translational Research"
- Feb 1995 Vanderbilt Endocrinology Grand Rounds, "The Malignant Carcinoid Syndrome: Management in the Somatostatin Era"
- April 1995 University of Tennessee, Knoxville, Medical Grand Rounds, "Somatostatin Receptor Scintigraphy in the Management of Neuroendocrine Cancer"
- May 1995 Uppsala, Sweden, Uppsala University, Medical Grand Rounds, "Carcinoid Syndrome: Survival in the Somatostatin Era"
- Jun 1995 Society of Nuclear Medicine Symposium, Minneapolis, "Effective Management of the Neuroendocrine Tumor Patient"
- Jun 1995 University of South Alabama, Mobile, AL, "The Effective Management of Neuroendocrine Tumors: Incorporating In-111 Pentetreotide into Clinical Practice"

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 24

- Sept 1995 Vanderbilt University Medical Oncology Core Curriculum: "Management of Paraneoplastic Metabolic Disorders"
- Sept 1995 LSU Medical Center, Stanley S. Scott Cancer Center: "Neuroendocrine Cancer: Management in the Somatostatin Era"
- Sept 1995 Vanderbilt University Medical Grand Rounds, "Effective Management of Neuroendocrine Cancer," in conjunction with Eric Krenning MD, PhD, Professor of Nuclear Medicine, Head Department of Nuclear Medicine, University Hospital Rotterdam, "Oncologic Applications of Somatostatin Receptor Scintigraphy"
- Nov 1995 Methodist Hospital, Houston, TX, Oncology Grand Rounds, "Neuroendocrine Cancer: Management in the Somatostatin Era,"
- Nov 1995 Sorrento, Italy, European Federation of Endocrine Societies, "Somatostatin Receptor Imaging: Predictive and Prognostic Considerations"
- Dec 1995 Vanderbilt Endocrinology Grand Rounds, "Somatostatin and Its Receptor in the Management of Hormonally Active Neuroendocrine Neoplasms"
- Jan 1996 University of Cincinnati, Medical Oncology/Hematology Grand Rounds, "Somatostatin and Its Receptor in the Management of Neuroendocrine Cancer"
- Jan 1996 University of Cincinnati, "Malignant Carcinoid Syndrome: Survival in the Somatostatin Analog Era"
- May 1996 Rome, Italy, International Neuroendocrine Investigators, "Octreotide Acetate in Malignant Carcinoid Syndrome: Evaluation of a Microencapsulated Formulation"
- Jun 1996 San Francisco, CA: 10th International Congress of Endocrinology, "Modern Diagnostic Techniques for the Detection of Neuroendocrine Disease"
- Jun 1996 Medical Center of Central Georgia, Macon, GA, "Somatostatin Scintigraphy in the Management of Hormonally Active Neoplasms"
- Jul 1996 LSU, Medical Grand Rounds, "Applications of Somatostatin and Its Receptor in Oncology"

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 25

- Aug 1996 University of South Florida, Moffitt Cancer Center, Tampa, FL.  
"Neuroendocrine Cancer: A Model for the Management of Somatostatin Receptor Expressing Neoplasms"
- Nov 1996 Yale University, New Haven, CT: "Somatostatin Receptor Imaging in Neoplastic Diseases"
- Nov 1996 Vienna, Austria, Satellite Symposium, "Novel Approaches in the Treatment of Neoplastic Diseases"
- Dec 1996 Washington University, St. Louis, MO, "Carcinoid Neoplasm and its Syndrome: Influence of Octreotide on Survival:
- Dec 1996 St. Louis University, St. Louis, MO, "Somatostatin Analogs: Past, Present and Future"
- Dec 1996 University of Washington, WA, "Clinical Applications of Somatostatin and its Receptor in Oncology"
- Jan 1997 Duke University, Durham, NC, "Novel Approaches to the Management of Somatostatin Receptor Expressing Neuroendocrine Neoplasms"
- Feb 1997 University of Vermont, Burlington, VT, "Carcinoid Syndrome: Present and Future Management"
- Feb 1997 Northwestern University, Lurie Cancer Research Center: "Radiolabeled Peptides in the Management of Somatostatin Receptor Expressing Neoplasms"
- Feb 1997 Southeastern Clinical Club, "Radiolabeled Somatostatin Analogues: Rationale and Results of a Pilot Study"
- Apr 1997 National Gnotobiotic Society Annual Meeting, New Orleans, LA. "Novel Approaches to the Management of Peptide Expressing Neoplasms"
- Apr 1997 Ivalo, Finland, Fourth International Workshop on Neuroendocrine Tumors -Recent Advances in Diagnosis and Treatment, "Octreotide LAR in carcinoid syndrome"
- May 1997 International Conference, Organizing Committee, Athens, Greece: "Cancer Research in the Year 2000"

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 26

- June 1997 M.D. Anderson Cancer Center, Orlando, FL, "Neuroendocrine Cancer Management: Somatostatin and its Analogs"
- Jun 1997 Federation of European Endocrine Societies, "Octreotide LAR: Results of a Multi-Center Randomized Trial in Carcinoid Syndrome", Sorrento, Italy
- Aug 1997 European Association of Nuclear Medicine, "Preliminary Results of a Phase I Indium-111 Pentetreotide Trial in Somatostatin Receptor Expressing Neoplasms", Glasgow, Scotland
- Sept 1997 Advances in Digestive Endocrine Tumors, Rome, Italy: "Somatostatin and its Analogs: New Formulations and Survival Impact in Carcinoid Neoplasm"
- Oct 1997 International Symposium on Somatostatin Analogs: Basic Update and Clinical Perspectives, Venice, Italy: "Phase I Trial of Lanreotide in Neuroendocrine Neoplasms"
- Oct 1997 Advances in Solid Tumors, Fall Oncology Conference, Texas Oncology, PA, Physicians Reliance Network, Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, "Somatostatin Analogues in Cancer Therapy," Captiva Island, FL
- Nov 1997 University of Colorado, Denver, CO, "Peptide Imaging in Malignancies: Implications for Therapy"
- Jan 1998 16<sup>th</sup> Annual Diabetes and Endocrinology Seminar, The Watson Clinic Foundation, Inc in conjunction with the American Association of Clinical Endocrinology, "Carcinoid Syndrome," Lakeland, FL
- Mar 1998 New Skills in Oncology Symposium, "Applications of Somatostatin and its Analogs in Oncology" Fraser Island, Australia
- Mar 1998 LSU New Orleans, "Targeting Specific Peptide Receptors as Cancer Therapy"
- Apr 1998 Allegheny University Medical Center (Hahneman), Philadelphia, PA, "<sup>111</sup>Indium Pentetreotide: Diagnostic and Therapeutic Applications"
- Apr 1998 Fox Chase Cancer Center of Temple University, Philadelphia, PA, "Carcinoid Syndrome: Diagnostic and Therapeutic Approaches"

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 27

- Apr 1998      The H. William Scott, Jr. Society, Department of Surgery, Vanderbilt University, "<sup>111</sup>Indium Pentetreotide: Report of a Phase II Trial in Neuroendocrine Malignancies"
- Jun 1998      30<sup>th</sup> Annual Meeting of the European Pancreatic Club, "Sandostatin LAR: Results of a Multi-center Randomized Trial in Carcinoid Syndrome," Thessaloniki, Greece
- Jan 1999      LSU, Medical Grand Rounds, "Carcinoid Syndrome"
- Feb 1999      Vanderbilt Endocrinology Grand Rounds, "Somatostatin and Its Analogs in the Treatment of Neuroendocrine Malignancies."
- Feb 1999      University of Tennessee, Knoxville, Oncology Grand Rounds, "Somatostatin and Its Analogs in the Treatment of Neuroendocrine Malignancies."
- Feb 1999      UCLA, Gastroenterology Grand Rounds, "Somatostatin and Its Analogs in the Treatment of Neuroendocrine Malignancies."
- Feb 1999      Cedars Sinai, Los Angeles, Oncology Grand Rounds, "Somatostatin and Its Analogs in the Treatment of Neuroendocrine Malignancies."
- Mar 1999      Sarasota Memorial Hospital, Wellness Center, "Carcinoid Syndrome: Diagnosis, Management and Future Directions" A Two day seminar program directed towards patients and physicians.
- Dec 1999      LSUHSC New Orleans, "Management of Hepatocellular Carcinoma"
- Mar 2000      Annual Review of Nuclear Medicine, Henry Wagner, Johns Hopkins University, "Oncologic Applications of Radiolabeled Somatostatin Analogs"
- Mar 2000      UCLA, Gastroenterology Grand Rounds, "Current and Novel Approaches to the Management of Hepatocellular Carcinoma"
- Apr 2000      Svalbard, Spitsbergen, Norway, Fifth International Workshop on Neuroendocrine Tumors -Recent Advances in Diagnosis and Treatment, "Indium-111 Pentetreotide Clinical Trials"

Curriculum Vitae continued

Lowell B. Anthony, M.D., F.A.C.P.

Page 28

- April 2001      LSUHSC New Orleans, "Update on Management of Advanced Colorectal Carcinoma"
- Sep 2001        Noordwijk, The Netherlands, Expanding the Role of Octreotide in Clinical Oncology Symposium, "Medical Uses of Octreotide Acetate Long Acting Formulation"
- Nov 2002        Academy for Healthcare-faculty participation in symposium Maximizing Oncologic Therapy
- Jan 2003        Symposium on Expanding Role of Octreotide in Oncology in Mont-Tremblant, Quebec
- May 2003        Symposium at Oncology Nurses Society Meeting in Denver, Co.
- May 2003        University of Mississippi, Jackson, MS "Vascular Endothelial Growth Factors (VEGF) in the Management of Colorectal Cancer"
- Aug 2003        LSUHSC New Orleans, "Management of Neuroendocrine Neoplasms from Protocol to Clinical Practice"
- Sep 2003        Copenhagen, Denmark, ECCO 12, The Expanding Role of Somatostatin Analogues in Oncology, "Octreotide Acetate LAR in the experimental treatment of diarrhea due to oncological intervention"
- Feb 2004        St. Kitts, Virgin Islands, Participation as distinguished faculty member at CME Con. "2nd Annual Future of Supportive Therapy in Oncology: An International Congress"
- Mar 2004        Budapest, Hungary, Participation as panelist "European Network of Endocrine Tumors Annual Meeting"